Literature DB >> 16893662

Susceptibility of vaginal bacteria to metronidazole and tinidazole.

M N Austin1, L A Meyn, S L Hillier.   

Abstract

In vitro antimicrobial susceptibility testing was performed on 470 vaginal isolates from women with bacterial vaginosis and three species of Lactobacillus, to metronidazole and tinidazole using the agar dilution method. There was no significant difference observed in the inhibitory activity of either drug to any of the isolates tested.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893662     DOI: 10.1016/j.anaerobe.2006.06.002

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  5 in total

1.  A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM.

Authors:  JoonHo Lee; Roberto Romero; Sun Min Kim; Piya Chaemsaithong; Chan-Wook Park; Joong Shin Park; Jong Kwan Jun; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-09-16

2.  Susceptibility of bacterial vaginosis (BV)-associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin.

Authors:  Melinda A B Petrina; Lisa A Cosentino; Lorna K Rabe; Sharon L Hillier
Journal:  Anaerobe       Date:  2017-05-15       Impact factor: 3.331

3.  Tinidazole in the treatment of bacterial vaginosis.

Authors:  Nicola R Armstrong; Janet D Wilson
Journal:  Int J Womens Health       Date:  2010-08-09

4.  Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses.

Authors:  Jack D Sobel; Navkiranjot Kaur; Nicole A Woznicki; Dina Boikov; Tina Aguin; Gurveer Gill; Robert A Akins
Journal:  Infect Drug Resist       Date:  2019-07-24       Impact factor: 4.003

5.  Guidelines for the treatment of bacterial vaginosis: focus on tinidazole.

Authors:  Laura J Dickey; Michael D Nailor; Jack D Sobel
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.